Johnson & Johnson is considering a spin-off of its hips-and-knees business, according to Chief Financial Officer Joseph Wolk. In a recent interview, Wolk stated that the company believes this move would provide the best value for its shareholders at this time.
The potential spin-off represents a significant step for the healthcare giant, which has previously explored options for divesting its orthopedic segment. Reports suggest that Johnson & Johnson has engaged in discussions with Apollo Global Management regarding a deal estimated at around $20 billion.
This announcement comes as Johnson & Johnson also raised its earnings forecast, even as it faces pressure from ongoing talcum powder lawsuits that have impacted its profits. The company has been embroiled in legal battles over claims that its talc-based products cause cancer, leading to a turbulent financial outlook.
The decision to consider spinning off the hips-and-knees business aligns with Johnson & Johnson’s broader strategy to streamline operations amidst financial challenges. The spin-off, if finalized, could reshape the company’s portfolio and focus, steering resources towards core areas of growth. The timeline for any potential transaction has not been disclosed.
As the company moves forward, it continues to navigate its legal challenges while exploring options to enhance shareholder value.
